Glenmede Investment Management, LP Axsome Therapeutics, Inc. Transaction History
Glenmede Investment Management, LP
- $20 Billion
- Q3 2025
A detailed history of Glenmede Investment Management, LP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Glenmede Investment Management, LP holds 7,232 shares of AXSM stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,232
Previous 8,287
12.73%
Holding current value
$1.01 Million
Previous $865 Million
99.9%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AXSM
# of Institutions
410Shares Held
38.5MCall Options Held
771KPut Options Held
578K-
Vanguard Group Inc Valley Forge, PA4.18MShares$584 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$461 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.33MShares$186 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY1.12MShares$156 Million1.82% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$151 Million0.16% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...